Assessment of Cancer Risk from Fluorscopic Bile Duct Examinations at Sanjiwani Hospital, Gianyar

Aim: Study on the Assessment of Cancer Risk from Fluoroscopic Bile Duct Examinations at Sanjiwani Hospital, Gianyar the aim is to determine the magnitude of the effective dose received by bile duct patients during fluoroscopic, to determine whether there is a difference between male and female patients in terms of the effective dose, and to determine the risk of cancer in bile duct examinations using fluoroscopic. Study Design: This study uses a quantitative analysis design using secondary data. This study was conducted at the Radiology Unit of Sanjiwani Gianyar Hospital from December 2024 to Febuary 2025. Methodology: This study involved 30 biliary tract patients. Data were analyzed using IBM SPSS and Excel software and for statistical tests using normality test, homogeneity test, one-way t-test, and one WAY ANOVA test to determine the risk of cancer in biliary tract examination with fluoroscopic. Results: After carrying out t-test for the absorbed dose, effective dose and cancer risk which were compared with the BAPETEN and ICRP values, the following result were obtained namely where the absorbed dose value was found to be below the safe threshold set by BAPETEN, which is 50 mGy. And where the effective dose value was found to be below the safe threshold set by BAPETEN, which is 10 mSv. And for the cancer risk value, it was found to be below the safe threshold set by ICRP, which is 0.08%. Conclusion: It is known that the values for the absorbed dose, effective dose, and risk of cancer received by patients at Sanjiwani Gianyar Regional Hospital are still below the values set by BAPETEN and ICRP so that they do not endanger patients undergoing bile duct cancer treatment at the Sanjiwani Gianyar Radiology Installation.